Phenotype, biochemical features, genotype and treatment outcome of pyridoxine-dependent epilepsy

Area of Science:

• Biochemistry and Genetics
• Neurology and Clinical Medicine

Background:

• Pyridoxine-dependent epilepsy (PDE) is a rare genetic disorder caused by pathogenic variants in the ALDH7A1 gene.
• Elevated alpha-aminoadipic semialdehyde (α-AASA) levels are a biochemical hallmark of PDE-ALDH7A1.
• Treatment typically involves pyridoxine, but neurodevelopmental outcomes can vary.

Purpose of the Study:

• To report treatment outcomes in eleven patients with PDE-ALDH7A1.
• To develop and apply a clinical severity score correlating phenotype with genotype and biochemical markers.
• To evaluate the impact of early dietary interventions (lysine-restricted diet) and arginine therapy on neurodevelopmental outcomes.

Main Methods:

• Development of a clinical severity score (1-9) based on global developmental delay, age of seizure onset, and current seizure status.
• Analysis of genotype (truncating vs. missense variants), biochemical data (α-AASA levels), and treatment regimens (pyridoxine, arginine, lysine-restricted diet).
• Comparison of phenotypic severity across different genetic and biochemical profiles, and in relation to treatment timing and type.

Main Results:

• Phenotypes ranged from mild to severe, with no clear correlation between α-AASA levels or genotype and severity.
• Pyridoxine alone achieved seizure freedom in 73% of patients; 25% had mild phenotypes on monotherapy.
• All patients (100%) receiving a lysine-restricted diet initiated within the first 7 months of life exhibited mild phenotypes.

Conclusions:

• Early initiation of a lysine-restricted diet, particularly within the first 7 months, is crucial for achieving mild phenotypes in PDE-ALDH7A1.
• Arginine therapy may also contribute to improved neurodevelopmental outcomes.
• The study highlights the importance of timely and comprehensive treatment strategies for optimizing outcomes in PDE-ALDH7A1.